CN106420853A - Medical health applications of sea buckthron oil for mucosal repair and nutrition - Google Patents
Medical health applications of sea buckthron oil for mucosal repair and nutrition Download PDFInfo
- Publication number
- CN106420853A CN106420853A CN201610717245.5A CN201610717245A CN106420853A CN 106420853 A CN106420853 A CN 106420853A CN 201610717245 A CN201610717245 A CN 201610717245A CN 106420853 A CN106420853 A CN 106420853A
- Authority
- CN
- China
- Prior art keywords
- mucosa
- oleum hippophae
- skin
- group
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036541 health Effects 0.000 title claims abstract description 9
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 7
- 230000035764 nutrition Effects 0.000 title claims abstract description 7
- 230000008439 repair process Effects 0.000 title abstract description 4
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 20
- 210000004877 mucosa Anatomy 0.000 claims abstract description 19
- 241000222122 Candida albicans Species 0.000 claims abstract description 16
- 210000001156 gastric mucosa Anatomy 0.000 claims abstract description 16
- 229940095731 candida albicans Drugs 0.000 claims abstract description 15
- 230000006378 damage Effects 0.000 claims abstract description 10
- 210000001215 vagina Anatomy 0.000 claims abstract description 10
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims abstract description 3
- 241000229143 Hippophae Species 0.000 claims description 55
- 235000003935 Hippophae Nutrition 0.000 claims description 54
- 208000027418 Wounds and injury Diseases 0.000 claims description 24
- 206010052428 Wound Diseases 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 11
- 210000000981 epithelium Anatomy 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 8
- 210000001647 gastrula Anatomy 0.000 claims description 6
- 230000012292 cell migration Effects 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 4
- 230000008066 mucocutaneous inflammation Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000002496 gastric effect Effects 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 201000010927 Mucositis Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 13
- 241000700159 Rattus Species 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 229940027941 immunoglobulin g Drugs 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 8
- 102400001368 Epidermal growth factor Human genes 0.000 description 7
- 101800003838 Epidermal growth factor Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229940116977 epidermal growth factor Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000005141 Otitis Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000003629 gastrointestinal hormone Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- SFCVEUVVOJFYSX-UHFFFAOYSA-J [Pb+2].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].C(C)(=O)[O-].[U+6] Chemical compound [Pb+2].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].C(C)(=O)[O-].[U+6] SFCVEUVVOJFYSX-UHFFFAOYSA-J 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 125000000017 cortisol group Chemical group 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention belongs to the technical field of medicine health care, and in particular discloses applications of sea buckthron oil. The sea buckthron oil is used for preparing the medicines, foods or health products used for mucosal repair and nutrition, and the mucosa is skin mucosa, gastric mucosa or vaginal epithelial mucosa; the sea buckthron oil has the inhibiting effect for the skin mucosa inflammation; the sea buckthron oil has the effects of repairing the wound of the skin mucosa and promoting the growth of skin factors; the sea buckthron oil has the protection effect for the gastric mucosal damage; the sea buckthron oil can inhibit the formation of candida albicans hyphae and the adhesion of blastospores for epithelial cells of the vagina, and recover the state and vitality of the epithelial cells of the vagina.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of Oleum Hippophae is used for the medicines and health protection of cell migration and nutrition
Purposes.
Background technology
Oleum Hippophae (sea backthorn oil), is that the preciousness for extracting from the fruit of natural plants Fructus Hippophae is natural
Oils and fatss.Except containing in addition to unsaturated fatty acid in sea buckthorn fruit, also containing flavone, vitamin, plant sterol, trace element and
100 various bioactivators such as alpha-tocopherol.In Fructus Hippophae extract Oleum Hippophae rich in VE, carotene, carotenoid, β-
Sitosterol, unsaturated fatty acid etc., can promote body metabolism, are conducive to the organized renewing for damaging, can also prevent subcutaneous group
The development of tissue inflammation, antiinflammatory granulation promoting, and significantly promote ulcer healing effect.Thus Oleum Hippophae is clinically damaged to radiation
Wound, burn, scald, decubital ulcer, dermatitis, mucositiss, endometritis, cervical erosion stomach function regulating and duodenal ulcer etc. have good treatment
Effect, Oleum Hippophae oral administration and externally still has better effects to treating chloasma, chronic skin ulcer.To wound healing after operation, disappear
Except pain, reduce untoward reaction, also have fine effect.Total flavones in Fructus Hippophae have Direct Acquisition oxygen-derived free radicals and hydroxy radical to make
With.The internal free radical of VE, VC, superoxide dismutase (SOD) energy antioxidation, removing, while have enhancing immunologic function again, adjusts
Save immunologically competent cell, be conducive to improving human disease resistance, delaying human body caducity.Multiple biological nutrient that Fructus Hippophae is rich in
To nursing skin, wrinkle resistant anti-ageing also have good effect.
Mucosa refers to that oral cavity, nasal cavity, intestinal tube, vagina, intestinal etc. communicate the moistening lining of body cavity with the external world.Gastric mucosa is to deposit
It is one layer of very thin, very fragile mucosal tissue of stomach inwall, such as same stifled natural " barrier " safety that protect coat of the stomach.It
With the homeostatic mechanisms for damaging with self-regeneration, the normal operation of stomach is protect.Once the external world gives the negative of stomach
Load is overweight or stimulation is too strong, and dynamic equilibrium will be broken, and gastric acid just starts " self-digestion " to coat of the stomach, is formed then recessed
The breakage on surface.Gastric mucosa is once impaired, is difficult to recover again as before.The thing followed is exactly epigastric discomfort or pain, evil
The symptom of the series of gastric such as the heart, vomiting, diarrhoea, inappetence discomfort.Expert points out, protection gastric mucosa escapes injury, except
Undesirable element to be reduced to the stimulation of stomach outside, also need while repair and protect relatively fragile gastric mucosa, to be so just avoided that stomach
Disease occurs and recurs.Protecting human body is got up by skin and mucosa, makes human body define a closed system to external world, when harmful
When material will invade human body, it is that extraneous paathogenic factor is stopped in vitro by skin and mucosa first.So skin and mucosa are
Human body anti-infective the first line of defence.Vaginal mucosa refers to the holding vaginal walls surface wettability of vaginal walls secretion, keeps table
The mucus film layer of face vigor, because how sticky its surface is, therefore is mucosa.In follicular phase, vaginal mucosa receives estrogen action, epithelium
Thicken, epidermis cell keratinization；Abundant (the note of glycogen in vaginal epithelial cell：Vaginal mucosal epithelium is stratified squamous epithelium also known as " answers
Layer squamous epithelial cancer "), lactic acid being decomposed under bacterium vaginae effect, keeps the sour environment of vagina；After ovulation, made by progestogen
With vaginal mucosal epithelium comes off in a large number, and keratinization phenomenon disappears.
Protection at present to mucosa and the reparation overwhelming majority are treated using Western medicine.In drug treatment, although western
Medicine has a certainly curative effect, but expensive, toxic and side effects are big etc., and medication problem is day by day projected, and the year after next relapse rate that is discontinued is up to
70% or so.Chinese medicine is made great progress to the Therapy study of mucosa in recent years, low, secondary with stable curative effect, relapse rate
The few advantage of effect.Oleum Hippophae is rich in VE, carotene, carotenoid, cupreol, unsaturated fatty acid etc., can promote machine
Body metabolism, is conducive to the organized renewing for damaging, can also prevent the development of subcutaneous tissue inflammation, antiinflammatory granulation promoting, and substantially
Promotion ulcer healing effect.Pharmacological tests show that Oleum Hippophae has antiinflammatory, analgesia, improves immunity of organisms, protects and repair
The effects such as multiple breakage mucosa, promotion skin factor growth.
Content of the invention
It is an object of the invention to provide a kind of Oleum Hippophae is used for the medicines and health protection purposes of cell migration and nutrition.
The technical solution adopted in the present invention is, Oleum Hippophae preparing for the medicine of cell migration and nutrition or food or
Application in health product.
The feature of the present invention is also resided in,
Mucosa is mucocutaneous, gastric mucosa or vagina epithelium mucosa.
Oleum Hippophae is inhibited to mucocutaneous inflammation.
Oleum Hippophae to the reparation of mucocutaneous wound face and promotes the effect that skin factor (EGF) grows.
Oleum Hippophae has protective effect to gastric mucosa injury.
Oleum Hippophae can suppress the adhesion of the formation and blastopore of candida albicans bacterium mycelia to vaginal epithelial cell, extensive
The multiple form of vaginal epithelial cell and the effect of vigor.
The details of various aspects of the present invention will be described in detail in subsequent chapters and sections.By hereafter and claim
Description, the feature of the present invention, purpose and advantage will become apparent from.
Description of the drawings
Fig. 1 is the measurement figure of wound surface diameter；
Fig. 2 is (× 3000) mycelia figure under high power lenses；
Fig. 3 is (× 3000) vaginal epithelial cell figure under high power lenses.
Specific embodiment
The present invention is described in detail with reference to the accompanying drawings and detailed description.
First, mucocutaneous antiinflammatory action test
(1) test medicine：Oleum Hippophae, is supplied by Haitian Pharmacy Co., Ltd., Shaanxi, water-soluble with 3% Tween 80 during test
Liquid prepares desired concn；
(2) animal：White mice (ICR germline), rat (SD germline), solid feed is fed.All by Xi'an Communications University
Medical college Experimental Animal Center is supplied, and arranges the quality certification for the dynamic card word 04 of Shan doctor, and the certification of fitness is the dynamic card word 05 of Shan doctor.
(3) method and result
1. white mice Oleum Tiglii ear inflammation method
Select male white mouse 40,25～27 grams of body weight, divide equally 4 groups at random by body weight, 1 group be
According to group；2nd, 3 groups are respectively 10% and 20% Oleum Hippophae medicine group；4 groups of hydrocortisone groups.Each group mice uniformly applies bar in left ear
Oleum Glycines mixed liquor 0.06ml/ only causes inflammation.After causing scorching half an hour, the left ear of 1 group of Mus applies 3% Tween 80 aqueous；2nd, 3 groups of Mus are respectively on a left side
Ear applies 10% and 20% Oleum Hippophae medicinal liquid；4 groups of left ears apply hydrocortisone liquid.(the loose parenteral solution 100mg/20ml that hydrogen can be changed).
Coating volume is only all 0.1ml/.Causing inflammation after 3.5 hours, ear skin residual liquor is gently wiped with cotton balls.Cause scorching 4
After hour, de- cervical vertebra puts to death mice, cuts left and right two ear along the ear portion and overlaps together, with eye scissors in left and right ear identical portions
Position is trimmed to the auricle of onesize shape, is weighed with torsion balance respectively.The left and right ear weight difference of mice is calculated, is that inflammation swells
Swollen level index.Each group Mus otitis disease swelling degree is carried out statistical procedures.As a result as table 1.
Impact of the 1 Oleum Hippophae dermatologic of table to mouse knoting oil otitis disease
As a result show, 10% Oleum Hippophae medicine, or 20% Oleum Hippophae medicine ear skin local application, white mice Oleum Tiglii is caused
Ear inflammation, all has obvious inhibitory action (p ＜ 0.01).
2nd, Oleum Hippophae is studied to skin ultrastructure
1. material
1.1 instrument
Inverted microscope (Nikon), Biohazard Safety Equipment (HealForce), CO2 incubator (Thermo), Syrup-homogenizing instrument
(IKA), refrigerated centrifuge (Eppendrof), spectrophotometer (Bio-RAD), slide gauge (Wollschlger).
1.2 reagent
Oleum Hippophae (Haitian Pharmacy Co., Ltd., Shaanxi), RPMI1640 (GIBCO), hyclone (GIBCO), cell dissociation
Liquid (Invitrogen), PBS liquid (GIBCO), MTS cell proliferation immue quantitative detection reagent box (Promega), Rat epidermal growth because
Sub- test kit (R＆D).
1.3 cells and animal
Rat dermal fibroblasts (from 3 day-old Wistar neonatal rat skin of back), male 5 week old Wistar rat
(Beijing Vital River Experimental Animals Technology Co., Ltd.'s offer)
2. method
The making of 2.1 wounds in animals models, packet and medication
2.1.1 5 week old Wistar rats of modeling male, are cooked 2 circular wound surface, each diameter 20mm in back spinal column both sides
As deep as fascia.
2.1.2 packet with administration rat is divided into 5 groups, per group 6.Wherein 1 group of matched group is not administered, 4 groups of administration groups, gives
Concentration is 100,200,300,400 μ g/ml (dissolving medicine using PBS).Each wound surface administration 1ml, edge of wound subcutaneous injection.Cloudy
Property matched group injection 1mlPBS liquid, positive controls inject PBS liquid 1ml containing 200U.The wound same day starts administration, once a day,
Stop administration after successive administration 10d.
2.2 wound surface are measured
The measurement result of the diameter meansigma methodss as the sample of 2 wound surface is taken during measurement.Whole experimental period is to heal most
Slow 1 group was healed completely for the off period.Due to not pressing regular circle shapes healing during wound healing, so each wound per only rat
The diameter of 4 diverse locations of measurement, averages as the wound diameter.
The measure of 2.3 cytokines
After modeling, 1d starts to take edge of wound skin, then takes edge of wound skin every 3d.0.1mol/ is added by per gram of skin
The amount homogenate of LPBS15ml, is homogenized and is centrifuged 30min in 4 DEG C of 15000r/min, take supernatant for the measure of cytokine.Rat table
The measure of skin growth factor (EGF) is carried out according to kit specification.
2.4 statistical method
Checked using t, data are analyzed using SPSS115, and data are represented with x ± s, P ＜ 0.05 is for there were significant differences.
3 results
The measurement of wound surface size in 3.1 agglutinations
As Fig. 1 shows, at the 16th day, healing at first was finished the experimental group of 300 μ g/ml of administration, was secondly 400 μ g/ml of administration
Experimental group and positive controls the 18th day healing finish, the 3rd for administration 200 μ g/ml experimental group healed at the 19th day
Finish, the 4th finishes in healing in the 20th day for 100 μ g/ml of administration, the 5th is that negative control group is finished in healing in the 23rd day.
The determination data comparative approach of 3.2 cytokines be measure the same day each administration group respectively with negative control group, sun
Property matched group compares, statistically significant as difference with P ＜ 0.05.Due to there is experimental group to heal before the 16th measurement day completely
Close, therefore only list and compare the 16th measurement day and data before.
3.2.1 epidermal growth factor (EGF) table 2 shows, each concentration group EGF content of Oleum Hippophae starts dense with medicine from experiment
Degree increases and increases, and all low than positive controls.During last 1 administration in the 10th day, each experimental group EGF reaches peak value, and
Each administration group is below positive controls.In addition to the 1st day measured value, 300 μ g/ml groups are during each concentration group administration of Oleum Hippophae
EGF content highest.
2 EGF of table measure (N=6) (pg/ml)
Note：* P ＜ 0.05 is compared with positive controls；Compare with negative control group：#P ＜ 0.05
3rd, test of the Oleum Hippophae to gastric mucosa injury
(1) test medicine；Oleum Hippophae, is supplied by Haitian Pharmacy Co., Ltd., Shaanxi, water-soluble with 3% Tween 80 during test
Liquid prepares desired concn；
(2) animal：White mice (ICR strain), is supplied by Xi'an Jiaotong University Medical College's Experimental Animal Center.Quality is closed
Lattice card is the dynamic card word 05 of Shan doctor.
(3) dosage choice：The human body recommended amounts of Oleum Hippophae are daily 2g/60kg.bw, and experiment sets 3 dosage groups, i.e.,：
0.17g/kg.bw group (low), 0.33g/kg.bw group (in) and 0.99g/kg.bw (height) group, the dosage of basic, normal, high 3 groups divide
Not Wei 5 times, 10 times, 30 times of human body recommended amounts, with 1% sodium carboxymethyl cellulose, sample is assigned to desired concn, while setting up
1% sodium carboxymethyl cellulose matched group, by 1ml/100g body weight gavage 30d.
(4) instrument and reagent：Digimatic calipers, dehydrated alcohol, formaldehyde.
(5) method and result
1. experimental technique：Rat 40 is taken, 4 groups are randomly divided into, dosage group gavage Oleum Hippophae, 1% carboxylic first of matched group gavage
Base sodium cellulosate, continuous 30d, water 24h is can't help in animal fasting before dissecting.Experiment terminates after same day gavage tested material 1h that gavage is no again
Water-ethanol 1ml/ is only.Animal is put to death after 1h, takes stomach and fix 20min tailing edge greater gastric curvature in 10% formalin and cut off, clean in
Tolerant, with length and wide (being accurate to 0.01mm) of its congested and diffusivity bleeding band of vernier caliper measurement.Calculate filling per Mus
Blood and the gross area of diffusivity bleeding band.
2. result：After the impact of the rat pipe film injury that Oleum Hippophae causes to dehydrated alcohol gives Oleum Hippophae 30d, Fructus Hippophae
The gastric mucosa injury area of the middle and high dosage group of oil is significantly less than matched group (P<0.01、P<0.05), illustrate Oleum Hippophae to anhydrous second
The gastric mucosa injury that alcohol causes has certain protective effect.The results are shown in Table 3.
The impact of the gastric mucosa injury that 3 Fructrs Hippophae seed oil of table causes to dehydrated alcohol
As Oleum Hippophae can reduce rat gastric secretion and reduce total acid output and pepsin output, and can increase
Plus gastric wall in rats mucus amount.So, while invasion and attack factor is weakened, protection factor is enhanced again, so as to show good resisting
Ulcer function.Containing the fatty acid for extremely enriching in Oleum Hippophae, its total acid output of suppression stomach and increase stomach mucilage secretion amount
Effect may be relevant with the abundant fatty acid which contains.Research shows that fat or fatty acid play the role of gastric acid secretion inhibiting.
As fat or fatty acid can stimulate multiple gut hormones to discharge in proximal small bowel, such as gastric inhibitory polypeptide, pancreaotropic homone, intestinal class pancreas are high
Blood glucose element etc., and glucagon has protective effect, secretin and cholecystokinin also to have stimulation gastric mucosa table to gastric mucosa
Face epithelial cells mucus simultaneously strengthens the effect such as health lesion capability.Speculate, Oleum Hippophae is released possibly through stimulation proximal small bowel
Put the comprehensive function of multiple gut hormones to protect the damage of gastric mucosa.
4th, repairing test of the Oleum Hippophae to impaired vagina epithelium mucosa in vitro
(1) experimental technique：The vaginal epithelial cell of original cuiture is adhered to candida albicans bacterial strain, causes vagina epithelium
The change (content of the cytokine of secretion and IgG is reduced) of cellular prion protein and cell function；Then after will be impaired
Vaginal epithelial cell cultivate a period of time under the intervention of Oleum Hippophae, whether observation of cell form and function make moderate progress.
1. cell culture
In per 100mlK-SFM basic culture solution, 500 μ l ox pituitary extract (Bovine Pituitary are added
Extract, BPE) and recombinant human epidermal growth factor (Recombinant Epidermal Growth Factor, rEGF) is mixed
Close liquid；1ml mycillin liquid；500μlCaCl2Solution (final concentration of 0.4mM).In culture bottle, plus 4-6mlK-SFM, will culture
Bottle cap returns stubborn half-turn, is put into 5%CO2In 37 DEG C of constant incubators.When Microscopic observation cell covers with fusion culture bottle bottom about
During 80%-90%, passage can be carried out.Cell is made single cell suspension, is counted with blood counting chamber, adjust cell concentration
For 1 × 105/ml.
2. candida albicans bacterium culture
Candida albicans bacterium (ATCC-11006) transferred species on Sabouraud glucose agar, transferred species 1 time again after 2 days.
Wherein well-grown single bacterium colony is chosen, a little strain of picking is suspended in culture fluid, wash 2 times.Use blood counting chamber meter
Number, adjustment concentration is respectively 1 × 105/ml.Vaginal epithelial cell is co-cultured in six orifice plates with candida albicans bacterium.
IgG content in the cell supernatant that the detection of 3.ELISA method is collected
Collect the culture supernatant detection commercialization total IgG after candidiasis infection VEC.Experiment is divided into 4 groups：0 group is single
The VK2/E6E7 for solely cultivating；1 group is Candida albicans：VK2/E6E7 ratio is 1:1 co-cultures 1640 training of addition after 12h
Nutrient solution 24h；2 groups add 1640 culture 12 hours for VK2/E6E7 after be directly added into Oleum Hippophae 54mg/ml effect 24h；3 groups are
Candida albicans：VK2/E6E7 ratio is 1:1 co-cultures addition Oleum Hippophae 54mg/ml effect 24h after 12h.Collect four
The cell culture supernatant of group, in the aseptic EP pipe loaded on 2ml, is placed in be measured in -80 DEG C of refrigerators.Using ELISA Kit for
Immunoglobulin G (IgG) (Cloud-Clone company of the U.S.), model C EA544Hu test kit by specification is grasped
Make, standard substance and detected sample is added, standard curve is done, microplate reader detects OD450 value.
4. Electronic Speculum step
Experiment is divided into 4 groups：0 group of VK2/E6E7 for single culture；1 group is Candida albicans：VK2/E6E7 ratio
Example is 1:1 co-cultures addition RPMI-1640 24h after 12h；2 groups add 1640 culture 12 hours for VK2/E6E7 after be directly added into sand
Spine oil 54mg/ml acts on 24h；3 groups is Candida albicans：VK2/E6E7 ratio is 1:1 co-cultures addition Fructus Hippophae after 12h
Oily 54mg/ml acts on 24h.Be inoculated in 24 orifice plates, fix cell with 2.5% glutaraldehyde, then with fix after osmic acid more than 2h,
With 1% osmic acid fixative, 2 hours are fixed afterwards.70%th, 80%, 90%, 100% acetone serial dehydration.Epoxy resin mixed liquor, 37
DEG C soak 24h after embed.Using the double dyeing of acetic acid uranium-lead citrate after ultra-thin electron microscopic section.Surface sweeping electron microscopic observation each group vagina
The operative condition of epithelium and candida albicans bacterium.
(2) experimental result and analysis：
1. cells and supernatant IgG detects (as shown in table 4)
4 cells and supernatant IgG testing result of table
| Packet | Multiple holes 1 | Multiple holes 2 | Multiple holes 3 | Average |
| 0(V) | 0.632 | 0.512 | 0.777 | 0.640 |
| 1(V+C) | 0.248 | 0.248 | 0.215 | 0.237 |
| 2 (V+ sand) | 0.512 | 0 | 0.176 | 0.229 |
| 3 (V+ sand+C) | 0.536 | 0.391 | 0.464 |
As shown in Table 4, there is notable difference in the secretory volume of IgG between group, and Oleum Hippophae can when acting solely on epithelial cell
The secretion of IgG can be caused to reduce due to toxic action of medicine etc., but Oleum Hippophae is acted on is attacked by candida albicans bacterium
After cell, compared with simple candida albicans bacterium invasion and attack epithelial cell, the secretion of epithelial cell IgG can be obviously promoted, be strengthened
The immunologic function of cell.
2. the PRELIMINARY RESULTS of scanning electron microscope
After Oleum Hippophae treatment 24h, as shown in Fig. 2 the rod-short blastopore that in Fig. 2, arrow indication is dispersed in above；Middle
Arrow indication is the mycelia of fracture；Bottom arrow indication is to swallow the vaginal epithelial cell of fracture mycelium (in figure shows 3
Epithelial cell), under high power lenses, (× 3000) observe that mycelia substantially reduces, and only remain the rod-short blastopore being dispersed on a small quantity；3
Epithelial cell is swallowing the mycelia being broken off, and is around dispersed in a small amount of rod-short blastopore of distribution.As shown in figure 3, arrow institute
Refer to as vaginal epithelial cell, under high power lenses, (× 3000) show that vaginal epithelial cell form is good, and vigor is preferable, podocytic process adhesiveness
By force, epithelial cell after birth is relatively complete, the smooth epithelium of cell surface, and surface is covered with microvilluss and microvilluss ridge, i.e., in irregular
Netted plasma membrane gauffer is dredged, consistent with normal non-infected cells form.
The result explanation Oleum Hippophae can suppress the formation of candida albicans bacterium mycelia and blastopore thin to vagina epithelium
The adhesion of born of the same parents, recovers form and the vigor of vaginal epithelial cell, strengthens the immunologic function of cell, promote the reparation of vaginal mucosa.
Finally it should be noted that：Above example is only in order to illustrate technical scheme and unrestricted.This area
It is to be appreciated by one skilled in the art that still technical scheme can be modified and equivalent, without deviating from this
The spirit and scope of technical scheme, which all should be covered in the middle of scope of the presently claimed invention.
Claims (6)
1. Oleum Hippophae is used for medicine or food or the application in health product of cell migration and nutrition.
2. application according to claim 1, it is characterised in that the mucosa is mucocutaneous, gastric mucosa or vagina epithelium
Mucosa.
3. application according to claim 2, it is characterised in that Oleum Hippophae is inhibited to mucocutaneous inflammation.
4. application according to claim 2, it is characterised in that reparation and promotion of the Oleum Hippophae to mucocutaneous wound face
The effect that skin factor (EGF) grows.
5. application according to claim 2, it is characterised in that Oleum Hippophae has protective effect to gastric mucosa injury.
6. application according to claim 2, it is characterised in that Oleum Hippophae can suppress the formation of candida albicans bacterium mycelia
And adhesion of the blastopore to vaginal epithelial cell, recover the form of vaginal epithelial cell and the effect of vigor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610717245.5A CN106420853A (en) | 2016-08-24 | 2016-08-24 | Medical health applications of sea buckthron oil for mucosal repair and nutrition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610717245.5A CN106420853A (en) | 2016-08-24 | 2016-08-24 | Medical health applications of sea buckthron oil for mucosal repair and nutrition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420853A true CN106420853A (en) | 2017-02-22 |
Family
ID=58181855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610717245.5A Pending CN106420853A (en) | 2016-08-24 | 2016-08-24 | Medical health applications of sea buckthron oil for mucosal repair and nutrition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420853A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110721159A (en) * | 2019-11-12 | 2020-01-24 | 榆林学院 | Seabuckthorn oil restoration spray and preparation method thereof |
| CN115462528A (en) * | 2022-08-31 | 2022-12-13 | 中南大学湘雅三医院 | Natural food composition and its application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1583108A (en) * | 2004-05-26 | 2005-02-23 | 内蒙古草原兴发股份有限公司 | Health care product of hippophae rhamnoides oil |
-
2016
- 2016-08-24 CN CN201610717245.5A patent/CN106420853A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1583108A (en) * | 2004-05-26 | 2005-02-23 | 内蒙古草原兴发股份有限公司 | Health care product of hippophae rhamnoides oil |
Non-Patent Citations (1)
| Title |
|---|
| 臧茜茜 等: ""沙棘油功效成分及药理功能研究进展"", 《中国油脂》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110721159A (en) * | 2019-11-12 | 2020-01-24 | 榆林学院 | Seabuckthorn oil restoration spray and preparation method thereof |
| CN115462528A (en) * | 2022-08-31 | 2022-12-13 | 中南大学湘雅三医院 | Natural food composition and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2875805B1 (en) | Method for the isolation of glycoprotein-rich fungal extract and its use in anti-ageing cosmetic formulations | |
| KR101762750B1 (en) | Cosmetic composition for skin cell regeneration and wound healing the use there of containing absolute of Hibiscus syriacus L.flower | |
| CN107822948A (en) | With after-sun restorative, anti-oxidant, white-skinned face function composition and preparation method thereof | |
| CN107456509B (en) | A kind of external application biological agent and preparation method for vagina prevention, health care and treatment gynaecology genital inflammation | |
| CN106420853A (en) | Medical health applications of sea buckthron oil for mucosal repair and nutrition | |
| KR101505576B1 (en) | Composition against striae distensae with the extract of asparagus officinalis | |
| CN104971069B (en) | A kind of applications of the 3 loose Siberian cocklebur acid B of hydrogenation extracted in great Bai bolts bacterium in pharmacy | |
| Acharya et al. | A review on therapeutic utilities and purificatory procedure of Gunja (Abrus precatorius Linn.) as described in Ayurveda | |
| CN108514600A (en) | A kind of eye sticker and preparation method thereof | |
| CN101816689A (en) | Processing method of ginseng | |
| CN104055909A (en) | Application of compound donkey-hide gelatin pulp in preparation of medicament for menstrual period health care | |
| CN104703617B (en) | New spice extract fraction and application thereof | |
| CN106389477B (en) | A kind of preparation method and application of the full cellular plant oil extract of Gordonia terrae | |
| Hanafiah et al. | Formulation and evaluation of binahong leaves extract gel on wound healing of the palatal mucosa | |
| KR20150143912A (en) | Pharmaceutical composition for the prevention and treatment of disease by blue light comprising Spirulina maxima as an active ingredient | |
| EP2708232A1 (en) | Composition comprising a Centella asiatica plant suspension cell culture | |
| CN107519213A (en) | A kind of strong immune composition of shield stomach containing Hericium erinaceus extract and preparation method thereof | |
| CN109528708A (en) | Application of the Kaempferol in preparation treatment rhinitis drug | |
| CN104069237A (en) | Novel application and pharmaceutical composition of houttuynia cordata | |
| CN103520707B (en) | A kind of beneficial bacterium controls the compositions that bacterium prevention and therapy gynaecologic reproductive system infects | |
| CN106029113A (en) | Fractions of extracts of helichrysum having mucohadesive properties | |
| CN103816217A (en) | A traditional Chinese medicine mixture capable of delaying skin ageing, a preparation method thereof and applications thereof | |
| CN102068482A (en) | Orpine total flavones as well as extraction method and drug use thereof | |
| KR101681169B1 (en) | Composition comprising natural extract as effective ingredient for ameliorating or treating itch and preparation method of textile using the same | |
| CN108096503A (en) | Treat medicated wine composition of gynecological disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |